Virax Biolabs Group Statistics
Total Valuation
VRAX has a market cap or net worth of $8.12 million. The enterprise value is $1.34 million.
Important Dates
The last earnings date was Wednesday, February 5, 2025, before market open.
| Earnings Date | Feb 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
VRAX has 4.34 million shares outstanding. The number of shares has increased by 50.43% in one year.
| Current Share Class | 4.34M |
| Shares Outstanding | 4.34M |
| Shares Change (YoY) | +50.43% |
| Shares Change (QoQ) | +38.70% |
| Owned by Insiders (%) | 6.63% |
| Owned by Institutions (%) | 1.46% |
| Float | 3.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 58.84 |
| Forward PS | n/a |
| PB Ratio | 0.94 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.58, with a Debt / Equity ratio of 0.07.
| Current Ratio | 11.58 |
| Quick Ratio | 10.67 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -148.24 |
Financial Efficiency
Return on equity (ROE) is -90.63% and return on invested capital (ROIC) is -51.27%.
| Return on Equity (ROE) | -90.63% |
| Return on Assets (ROA) | -47.66% |
| Return on Invested Capital (ROIC) | -51.27% |
| Return on Capital Employed (ROCE) | -71.77% |
| Revenue Per Employee | $4,992 |
| Profits Per Employee | -$387,077 |
| Employee Count | 17 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.27 |
Taxes
| Income Tax | -136,661 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +124.76% in the last 52 weeks. The beta is 1.61, so VRAX's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | +124.76% |
| 50-Day Moving Average | 1.98 |
| 200-Day Moving Average | 1.92 |
| Relative Strength Index (RSI) | 48.69 |
| Average Volume (20 Days) | 304,260 |
Short Selling Information
The latest short interest is 59,011, so 1.36% of the outstanding shares have been sold short.
| Short Interest | 59,011 |
| Short Previous Month | 108,983 |
| Short % of Shares Out | 1.36% |
| Short % of Float | 1.54% |
| Short Ratio (days to cover) | 0.15 |
Income Statement
In the last 12 months, VRAX had revenue of $84,872 and -$6.58 million in losses. Loss per share was -$2.47.
| Revenue | 84,872 |
| Gross Profit | 33,598 |
| Operating Income | -6.28M |
| Pretax Income | -6.92M |
| Net Income | -6.58M |
| EBITDA | -6.12M |
| EBIT | -6.28M |
| Loss Per Share | -$2.47 |
Full Income StatementBalance Sheet
The company has $7.38 million in cash and $603,202 in debt, giving a net cash position of $6.78 million or $1.56 per share.
| Cash & Cash Equivalents | 7.38M |
| Total Debt | 603,202 |
| Net Cash | 6.78M |
| Net Cash Per Share | $1.56 |
| Equity (Book Value) | 8.42M |
| Book Value Per Share | 1.99 |
| Working Capital | 7.34M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.57 million and capital expenditures -$707,916, giving a free cash flow of -$5.28 million.
| Operating Cash Flow | -4.57M |
| Capital Expenditures | -707,916 |
| Free Cash Flow | -5.28M |
| FCF Per Share | -$1.22 |
Full Cash Flow StatementMargins
| Gross Margin | 39.59% |
| Operating Margin | -7,397.95% |
| Pretax Margin | -7,915.62% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |